Format

Send to:

Choose Destination
See comment in PubMed Commons below
Oncologist. 2014 Jul;19(7):702-3. doi: 10.1634/theoncologist.2013-0419. Epub 2014 May 27.

Phase II study of Afatinib as third-line treatment for patients in Korea with stage IIIB/IV non-small cell lung cancer harboring wild-type EGFR.

Author information

  • 1Samsung Medical Center, Seoul, Republic of Korea;
  • 2Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea;
  • 3Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea;
  • 4Boehringer Ingelheim Ltd. UK, Bracknell, United Kingdom;
  • 5Boehringer Ingelheim Korea, Seoul, Republic of Korea;
  • 6Boehringer Ingelheim China, Beijing, China.
  • 7Samsung Medical Center, Seoul, Republic of Korea; kpark@skku.edu.

Abstract

BACKGROUND:

This phase II single-arm trial evaluated afatinib, an irreversible inhibitor of the ErbB receptor family as third-line treatment of Korean patients with advanced non-small cell lung cancer (NSCLC) and tumors with wild-type EGFR. Currently, no standard therapy exists for these patients.

METHODS:

Eligible patients had stage IIIB/IV wild-type EGFR lung adenocarcinoma and had failed to benefit from two previous lines of chemotherapy but had not received anti-EGFR treatment. Patients received oral afatinib at 40 mg per day until disease progression or occurrence of intolerable adverse events (AEs). The primary endpoint was confirmed objective tumor response (OR) rate (confirmed complete response [CR] or partial response [PR]). Secondary endpoints included disease control rate (DCR; OR or stable disease for ≥6 weeks), progression-free survival (PFS), and safety.

RESULTS:

Forty-two patients received afatinib treatment, and 38 of those were included in efficacy analyses. No confirmed CRs or PRs were reported. DCR was 24% (9 of 38 patients), with a median disease control duration of 19.3 weeks. Median PFS was 4.1 weeks (95% confidence interval: 3.9-8.0). Frequently reported AEs (mainly grades 1 and 2) were rash/acne (88%), diarrhea (62%), and stomatitis (57%).

CONCLUSION:

Heavily pretreated patients with wild-type EGFR NSCLC treated with afatinib monotherapy did not experience an objective response and only 24% had disease stabilization lasting more than 6 weeks. AEs were manageable and consistent with the expected safety profile.

©AlphaMed Press; the data published online to support this summary is the property of the authors.

PMID:
24868099
[PubMed - indexed for MEDLINE]
PMCID:
PMC4077442
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk